Targeted treatment of PIK3CA‐mutant breast cancers with anti‐PIK3CA therapy is known to lead to a compensatory increase in ER‐dependent transcription and shift in ERα genomic binding that limits therapeutic efficacy.57, 58. The gene discussed is ESR1; the disease is breast cancer.